Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells by Yi Yu et al.
Yu et al. Journal of Experimental & Clinical Cancer Research 2014, 33:85
http://www.jeccr.com/content/33/1/85RESEARCH Open AccessTransactivation of epidermal growth factor
receptor through platelet-activating factor/receptor
in ovarian cancer cells
Yi Yu1,2,3, Mingxing Zhang1,2,3, Xiaoyan Zhang1,2,3, Qingqing Cai1,2,3, Zhiling Zhu1,2,3*, Wei Jiang1,2,3*
and Congjian Xu1,2,3,4*Abstract
Background: We previously identified platelet-activating factor receptor (PAFR) as being overexpressed in ovarian
cancer and found that its ligand PAF evoked EGFR phosphorylation using the phospho-antibody microarray. Epidermal
growth factor receptor (EGFR) are also overexpressed in ovarian cancer and contribute to the growth of ovarian cancer
cells. Here, we investigated the mechanisms of crosstalk between PAFR and EGFR signaling in ovarian cancer cells
to further determine whether the interaction between PAFR and EGFR synergistic contribute to the progression
of ovarian cancer.
Methods: Expression and localization of PAFR in several ovarian cancer cell lines were assessed by Western blot,
realtime-PCR and immunofluorescence. The ovarian cancer cells were stimulated with PAF or PAF and in some
experiments also pharmacological inhibitors. Phosphorylation of proteins in signaling pathways were measured
by Western blot. HB-EGF concentrations of the supernatant from stimulated ovarian cancer cells were measured
by enzyme-linked immunosorbent assay.
Results: Our data show that PAF increases EGFR phosphorylation through PAFR in a time- and dose- dependent
manner in SKOV-3 ovarian cancer cells. This transactivation is dependent on phospholipase C-β and intracellular
calcium signaling. This pathway is also Src tyrosine kinase- and metalloproteinase- dependent. PAF triggers EGFR
activation through the increased heparin-binding EGF-like growth factor (HB-EGF) release in metalloprotease-dependent
manner. Several studies involving EGFR transactivation through G-protein coupled receptor (GPCR) have demonstrated
EGFR-dependent increase in ERK1/2 phosphorylation. Yet in SKOV-3 cells, PAF treatment also increases ERK1/2
phosphorylation in a EGFR-independent manner.
Conclusions: The results suggest that in SKOV-3 ovarian cancer cells, PAF transactivates EGFR and downstream ERK
pathways, thus diversifying the GPCR-mediated signal. The crosstalk between PAFR and EGFR suggests a potentially
important signaling linkage between inflammatory and growth factor signaling in ovarian cancer cells.
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Platelet-activating factor (PAF), prostaglandins (PGs), and
lysophosphatidic acid (LPA) are the three major phospho-
lipid mediators implicated in many different biological
pathways in inflammatory diseases and cancers [1-4]. Lipid
mediators play a critical role in cancer initiation and
progression. PAF induces diverse cellular effects through its
specific receptor, PAFR, which belongs to the G-protein
coupled receptor (GPCR) family and transduces cell signals
via G-proteins and associated protein phosphorylation
cascades [5-7]. Many types of cells, when challenged with
PAF, showed the activation of tyrosine kinase [8] and
protein phosphorylation [9-11].
The epidermal growth factor (EGF) receptor (EGFR) is
upregulated in ovarian cancer, and increased expression
is associated with reduced survival rate [12-15]. EGFR is
emerging as an important therapeutic target for several
epithelial tumors, including ovarian cancer. Yet, recent
clinical trials targeting EGFR using cetuximab [16-18],
matuzumab [19,20], gefitinib [21], and erlotinib [22,23]
in epithelial ovarian cancer patients have shown only
modest clinical responsiveness. The modest responses of
EGFR blockade in response to the administration of
monoclonal antibodies or tyrosine kinase inhibitors as
single agents could be attributed to compensation through
other signaling pathways.
It has been reported that different mechanisms might
be involved in the crosstalk between GPCRs and EGFR
[24]. Several GPCR ligands have been shown to activate
the EGFR pathway contributing to carcinogenesis. PGE2
has been reported to activate the EGFR in hepatocarci-
noma [25]. EGFR activation in response to GPCR ligands,
including lysophosphatidic acid (LPA), has been reported
in HNSCC cells [26]. Thus, the combined inhibition of
EGFR and GPCR might enhance antitumor effects
compared with single agents targeting EGFR alone. In
our previous studies, we demonstrated PAFR gene and
protein overexpression in ovarian cancer tissues and a
series of ovarian cancer cell lines [27]. Phospho-antibody
microarray analysis revealed increased EGFR, Src, FAK and
Paxillin phosphorylation through PAF in OVCA429 and
OVCA432 cells. We also showed that the combined PAFR
and EGFR targeting synergistically inhibited the ovarian
cancer in vitro and in vivo [28]. However, the mechanisms
underlying EGFR phosphorylation through PAF/PAFR in
human ovarian cancer have not yet been tested.
In the present study, we examined the SKOV-3, a
well-characterized human serous ovarian cancer cell line
with high levels of endogenous functional PAF-receptor
expression, to characterize the interaction between the
pathways mediated through PAFR and EGFR. The aim of
this study was to determine whether PAF transactivates
EGFR in ovarian cancer cells, examine the involvement of
the PAFR in this process, and elucidate the intracellularsignaling mechanisms required for transactivation. Acti-
vating growth factor receptors through PAF might be
an important mechanism in mediating the downstream
mitogenic effects of PAFR. This transactivation might reveal
previously unknown associations between inflammatory
and growth factor signaling, providing a better understand-
ing of the relationship between inflammation and cancer.
Materials and methods
Cell culture and chemical reagents
The ovarian cancer cell lines SKOV-3, CAOV-3, OVC
A433, RMUG-L and ES-2 (obtained from the Cell Bank of
the Chinese Academy of Science, Shanghai, China) were
maintained at 37°C in a humidified 5% CO2 atmosphere in
RPMI-1640 medium supplemented with 10% fetal calf
serum (Gibco, Invitrogen, Carlsbad, CA), 100 IU/ml
penicillin G, and 100 mg/ml streptomycin sulfate (Sigma-
Aldrich, St. Louis, MO). The cells were serum starved
through incubation in serum-free medium for 12–24
hours before the start of the experiments. β-Acetyl-γ-O-
alkyl-L-α-phosphatidylcholine (PAF), epidermal growth
factor (EGF), WEB2086 (PAFR antagonist), AG1478
(EGFR inhibitor) and PP2 (Src inhibitor) were obtained
from Sigma-Aldrich (St. Louis, MO). U73122 (PLC
inhibitor), BAPTA-AM (calcium chelator), Thapsigargin
(Ca2+-ATPase inhibitor), GF109203X (PKC inhibitor),
and PMA (PKC activator) were obtained from Tocris
(Bristol, UK). The rabbit polyclonal antibodies used in
this study were directed against phospho/total-EGFR,
phospho/total-ERK, and phospho/total-Src. All antibodies
were purchased from Cell Signaling Technology (Boston,
MA). The mouse monoclonal antibodies used in this
study were directed against actin (Sigma, Missouri, USA).
Western blot analysis
Cellular extracts were prepared in modified radioimmuno-
precipitation assay (RIPA) buffer (50 mM Tris–HCl pH 7.4,
1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM
EDTA, 1 mM PMSF, and protease inhibitor cocktail). The
protein concentrations in the cellular extracts were mea-
sured using a Bio-Rad protein assay kit. The cellular extracts
were subjected to SDS-PAGE, and the proteins were trans-
ferred onto PVDF membranes. After blocking for 1 h at
room temperature in 5% BSA, the blots were incubated with
the primary antibody at a 1:1000 dilution and incubated
overnight at 4°C. Subsequently, the blots were washed three
times and incubated for 1 h at room temperature with a
1:10000 dilution of secondary peroxidase-conjugated anti-
bodies. After washing three times, the immunoreactive
bands were detected using electrochemiluminescence (ECL).
Quantitative real-time PCR
Total RNA was extracted using Trizol reagent (TaKaRa,
Japan) and reverse transcribed using the PrimeScript
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facturer’s instructions. Real-time PCR analyses were
performed using SYBR Premix Ex Taq (TaKaRa, Japan)
on a 7300 Real-time PCR system (Applied Biosystems,
Inc. USA) at the recommended thermal cycling settings:
one initial cycle at 95°C for 10 s, followed by 40 cycles
at 95°C for 5 s and 60°C for 31 s. The following primer
sequences were used for PAFR detection: sense, 5′- GG
GGACCCCCATCTGCCTCA -3′ and antisense, 5′- GC
GGGCAAAGACCCACAGCA -3′. The expression levels
were normalized to the internal reference gene 18S rRNA
(sense, 5′- GTAACCCGTTGAACCCCATT -3′ and anti-
sense, 5′- CCATCAATCGGTAGTAGCG -3′) [29].
Intracellular calcium measurement
Calcium mobilization was performed as described previ-
ously [30]. The SKOV3 cells were harvested with Cell
Stripper (Mediatech, Herndon, VA, USA), washed twice
with PBS and resuspended to 5 × 106 cells/ml in Hank’s
balanced salt solution(140 mM NaCl, 5 mM KCI, 10 mM
HEPES, pH7.4, 1 mM CaCI2, 1 mM MgCl2, 1 mg/ml
glucose) containing 0.025% BSA. Subsequently, the cells
were loaded with 3 μM Fura-2 acetoxymethyl ester
derivative (Fura-2/AM) (Molecular Probes, Eugene, OR,
USA) for 30 min at 37°C. The cells were washed once
in Hank’s solution, and then resuspended in Hank’s at a
concentration of 3 × 107 cells/ml. These cells were sub-
sequently stimulated with 100 nM PAF. The calcium
flux was measured using excitation at 340 and 380 nm
in a Tecan Infinite 200 pro series Microplate Reader
(Tecan, Switzerland). When required, the cells were
treated with WEB2086 for 1 hour in serum-free McCoy’s
5A medium prior to the experiment.
HB-EGF assay
Aliquots of the supernatant from stimulated ovarian
cancer cells were collected and the HB-EGF concentra-
tions were measured using a specific enzyme immuno-
assay kit (Cayman Chemical, Ann Arbor, MI). The assay
was performed according to the manufacturer’s instruc-
tions. HB-EGF production was evaluated in duplicates,
and the concentrations were determined from a standard
curve of HB-EGF. The sensitivity of the assay facilitated
detection of up to 15 pg/ml. When necessary, the samples
were diluted in the assay buffer.
Immunocytochemistry
Following drug treatment, the cells were fixed with 100%
methanol for 6 min at −20°C, washed with PBS and stored
at 4°C until further use. The cells were permeabilized
through incubation in PBS containing 0.3% Triton X-100
and 5% goat serum for 30 min. A polyclonal antibody
against phospho-EGFR was used at a 1:100 dilution,
and a secondary antibody FITC-conjugated goat anti-rabbit (Invitrogen, Carlsbad, CA), was used at a 1:200
dilution. The first antibody was incubated overnight at
4°C and the second antibody was incubated for 2 hours
at RT. The images were captured using an Olympus DP
71 camera (Tokyo, Japan) at 400× magnification.Statistical analysis
All experiments were performed at least three times.
The data are expressed as the means ± SD. Wherever
appropriate, the data were also subjected to unpaired,
two-tailed Student’s t-tests. The differences were consid-
ered significant at P < 0.05.Results
PAF increases EGFR phosphorylation in SKOV-3 cells
To determine the effects of PAF on EGFR transactivation
in ovarian cancer cells, we used SKOV-3 for further inves-
tigations. In SKOV-3 cells, stimulation with PAF (100 nM)
evoked EGFR phosphorylation in a time-dependent man-
ner, with maximal activation at 5 min and a subsequent
reduction to baseline after 25 min (Figure 1A). In addition,
increasing concentrations of PAF increased EGFR phos-
phorylation in a dose-dependent manner, reaching max-
imum levels at 100 nM (Figure 1B). Furthermore, the
phosphorylation of EGFR through PAF was inhibited
using AG1478 (20 μM) (Figure 1C), a specific EGFR in-
hibitor [31], providing further support for the induction of
EGFR transactivation through PAF in SKOV-3 cells.PAF-induced EGFR transactivation is dependent on the
PAF-receptor
We next investigated whether the PAF-receptor (PAFR)
is involved in the transactivation of EGFR in ovarian
cancer cells. Western blotting and reverse-transcription
polymerase chain reaction were used to examine five
ovarian cancer cell lines. As shown in Figure 2A and B,
PAFR expression was higher in SKOV-3, CAOV-3 and
OVCA433 cell lines, whereas PAFR expression was almost
absent in RMUG-L cells. The results were consistent
with those obtained in our previous study. We therefore
chose SKOV-3 and RMUG-L cells for use in additional
experiments. The staining intensity of phosphorylated
EGFR, following 10 min of 100 nM PAF treatment, was
much higher in SKOV-3 cells than in control cells, while
there was no obvious change between the PAF treatment
group and the control group in RMUG-L cells (Figure 2C
and D). Furthermore, in SKOV-3 cells, the activation of
EGFR through PAF was inhibited with increasing concen-
trations of WEB2086 [32], a specific small-molecular
inhibitor of PAFR (Figure 2E). These data indicate the
PAFR is required for EGFR transactivation in ovarian
cancer cells.
Figure 1 Effects of platelet-activating factor (PAF) on epidermal growth factor receptor (EGFR) activation in SKOV-3 cells. (A) SKOV-3
cells were treated with 100 nM PAF for 0, 5, 10, 15, 20, or 25 min. Following PAF treatment, the cells were lysed, and the lysates were evaluated
by Western blotting. Data were normalized to total EGFR protein expression and are expressed as fold-change (average ± S.E.M.) in phospho-EGFR
compared with vehicle-treated cells. Representative blots for phosphor/total-EGFR are shown. (B) SKOV-3 cells were treated with vehicle (0) or 0.1
to 1000 nM PAF for 5 min. Fold-phosphorylation data for immunoreactivity with antibodies against p-EGFR are shown in representative Western
blots. (C) SKOV-3 cells were treated with AG1478 (20 μM) for 1 hour before stimulation with PAF (100 nM) or EGF (5 ng/ml) for 5 min. Cells were
harvested and subjected to Western blotting. The data shown are representative of at least three independent experiments. Data were analyzed
using Student’s t-test. * p < 0.05.
Yu et al. Journal of Experimental & Clinical Cancer Research 2014, 33:85 Page 4 of 12
http://www.jeccr.com/content/33/1/85PAF activates ERK1/2 phosphorylation via both
EGFR-dependent and EGFR-independent pathways
ERK1/2 are kinases that promote survival and prolifera-
tion [33], and we have previously shown that ERK1/2
can be acutely activated through PAF and EGF receptor
signaling pathways. Next, we examined the role of EGFR
in the PAF-mediated activation of ERK1/2. As shown in
Figure 3A, SKOV-3 cells were exposed with PAF (100 nM),
and the stimulation evoked ERK1/2 phosphorylation in a
time-dependent manner, with maximal activation at 5 min
and a subsequent reduction to baseline after 20 min. We
pretreated serum-starved SKOV-3 cells with the EGFR-
specific small-molecule inhibitor AG1478 (20 μM), and the
results showed that AG1478 only slightly inhibited the
PAF-induced phosphorylation of ERK1/2 (Figure 3B). In
addition, as shown in Figure 3C, increasing concentrations
of AG1478 did not effectively inhibit the PAF-induced
ERK1/2 activation. These results indicate that ERK1/2
might be phosphorylated through PAF via EGFR-
dependent and EGFR-independent mechanisms in ovarian
cancer cells.
Involvement of calcium, but not PKC, in the PAF-induced
transactivation of EGFR
The available evidence indicates that G-protein coupled
receptors (GPCR) mediate the activation of phospholipase
C-β (PLCβ) leading to the formation of inositol trisphos-
phate (InsP3) and diacylglycerol (DAG) [34]. DAG directly
activates classical types of PKCs, and IP3 activates intracel-
lular Ca2+ [35]. Therefore, we then examined the potentialinvolvement of PLCβ in the transactivation of EGFR using
the PLC inhibitor U73122 (20 μM). SKOV-3 cancer cells
were pretreated with 20 μM of U73122 for 1 hour, followed
by PAF or EGF stimulation for 5 min. When cells were
treated with PAF, U73122 significantly inhibited EGFR
activation, while after treatment with EGF, U73122 only
slightly affected EGFR activation (Figure 4A).
We next tried to determine which pathways down-
stream of PLCβ mediate the PAF-induced transactivation
of EGFR. We observed the effects of the intracellular
calcium chelator BAPTA-AM and thapsigargin, which
increases intracellular calcium levels through the inhib-
ition of the sarco/endoplasmic reticulum Ca2+-ATPase’
(SERCA) pump, on the PAF-induced phosphorylation of
EGFR in SKOV-3 cells. The cells were pretreated with
BAPTA-AM for 1 hour prior to PAF or thapsigargin
stimulation for 5 min. As shown in Figure 4B, PAF and
thapsigargin induced EGFR phosphorylation, while
BAPTA-AM abrogated EGFR activation. Furthermore, we
measured the effects of PAF and the PAF-receptor antag-
onist WEB2086 on intracellular calcium mobilization.
As shown in Figure 4C and D, stimulation with PAF
(100 nM) elicited a rapid increase in intracellular Ca2+
mobilization in SKOV-3 cells, and the PAF-induced Ca2+
mobilization could be inhibited through pretreatment
with WEB2086 for 1 hour.
To determine whether PKC is a downstream pathways
of PLCβ involving in EGFR transactivation mediated
through PAF, SKOV-3 cells were pretreated with 20 μM of
the PKC inhibitor GF109203X for 1 hour, followed by
Figure 2 PAF receptor is required for EGFR transactivation in ovarian cancer cells. (A) Lysates from SKOV-3, CAOV-3, OVCA433, ES-2 and
RMUG-L cells were subjected to SDS-PAGE, followed by immunoblotting for PAFR. Actin was used as loading control. (B) The relevant mRNA levels
of PAFR in these five cell lines were tested by quantitative real-time PCR, and the data were normalized to 18S rRNA. For the immunofluorescence
staining of phosphorylated EGFR in SKOV-3 (C) and RMUG-L (D) cells, after 10 min of incubation without any drug or with 100 nM PAF, the cells were
labeled with a polyclonal antibody to phosphor-EGFR overnight, followed by incubation with fluorescent secondary antibody to phosphor-EGFR for
1 h and staining with DAPI for 10 min. (E) SKOV-3 cells were pretreated for 1 h with increasing concentrations of the PAFR antagonist WEB2086. The
cells were then stimulated with PAF (100 nM) for 5 min before they were harvested and subjected to Western blotting. The data shown are representative
of at least three independent experiments. Data were analyzed by Student’s t-test. * p< 0.05.
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As shown in Figure 4E, little EGFR inhibition was ob-
served when SKOV-3 cells were treated with GF109203X;
however, treatment with GF109203X resulted in dramatic
decreases in ERK1/2 activation followed by stimulation
with PAF or PMA (Figure 4F). These results suggest that
Ca2+, rather than PKC, mediated the PAF-induced trans-
activation of the EGFR via PLCβ activation.Role of Src and metalloproteinases in the transactivation
of EGFR
To further elucidate the mechanisms underlying the
induction of EGFR transactivation through PAF, we
investigated the role of Src kinases. In SKOV-3 cells, PAF
stimulation led to the activation of Src kinases in a time-
dependent manner, with maximal activation at 5 min
and a subsequent reduction to baseline after 25 min
Figure 3 PAF activates ERK1/2 signaling via both EGFR-dependent and EGFR-independent pathways. (A) SKOV-3 cells were treated with
100 nM PAF for 0, 5, 10, 15, or 20 min. Following PAF treatment, the cells were lysed, and the lysates were evaluated by Western blotting. Data
were normalized to total ERK protein expression and are expressed as fold-change (average ± S.E.M.) in phospho-ERK compared to vehicle-treated
cells. Representative blots for phosphor/total-ERK are shown. (B) SKOV-3 cells were treated with AG1478 (20 μM) for 1 hour before stimulation with
PAF (100 nM) or EGF (5 ng/ml) for 5 min. Cells were harvested and subjected to Western blot. (C) SKOV-3 cells were pretreated for 1 h with increasing
concentrations of the EGFR inhibitor AG1478. Cells were then stimulated with PAF (100 nM) for 5 min before they were harvested and subjected to
Western blot. The data shown are representative of at least three independent experiments. Data were analyzed by Student’s t-test. * p < 0.05.
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the Src inhibitor PP2 (20 μM) abolished the PAF-
induced phosphorylation of EGFR, but, had little effect
on the phosphorylation of EGFR elicited through EGF.
These results suggest the involvement of a Src family
kinase in the PAF-induced transactivation of EGFR in
SKOV-3 cells.
Previous evidence has implicated proteinases of the A-
disintegrin-and metalloproteinase (ADAM) family in EGFR
transactivation through GPCRs in various cells [36]. To
examine the role of ADAMs in PAF-induced EGFR
transactivation in SKOV-3 cells, we pretreated the cells
with GM6001, a broad-spectrum metalloproteinase inhibi-
tor. As shown in Figure 5C, this pretreatment resulted in
the inhibition of PAF-induced EGFR phosphorylation,
while the EGF-induced phosphorylation of these proteins
was not affected. In addition, we pretreated cells with
increasing concentrations of GM6001 and observed that
GM6001 inhibited the EGFR phosphorylation in a dose-
dependent manner (Figure 5D). These results indicate that
transactivation is dependent on mechanisms involving the
ADAM-mediated release of EGFR ligands.
PAF-induced EGFR transactivation occurs via MMP-
mediated release of HB-EGF
EGFR can be activated through several ligands. EGFR
ligands bind to the extracellular domain of EGFR, trigger-
ing signaling downstream cascades, including MAPK
[37-39]. As shown in Figure 6A, SKOV-3 cells were pre-
treated with the HB-EGF neutralizing antibody for 1 hour,
followed by PAF or EGF stimulation for 5 min, and this
treatment inhibited PAF-induced EGFR phosphorylation,
while the EGF-induced phosphorylation of these proteinswas hardly affected. As shown in Figure 6B, in SKOV-3
cells, HB-EGF production increased after 30 min of
stimulation with PAF (100 nM) and continued to increase,
reaching a maximum after 2 hours. Longer PAF stimula-
tion caused no significant additional increase in HB-EGF
release over that obtained at 2 hours. In addition, we
examined the effects of the metalloproteinase inhibitor
GM6001 on HB-EGF production in SKOV-3 cells. The
cells were pretreated with GM6001 and the HB-EGF
neutralizing antibody for 1 hour prior to PAF stimulation
for 2 hours. Using an enzyme-linked immunosorbent
assay, we analyzed HB-EGF production in the medium of
SKOV-3 cells. HB-EGF levels increased in the medium
after PAF stimulation and GM6001 treatment inhibited
PAF-induced HB-EGF production (Figure 6C). These
results indicated that the ADAM-mediated release of
HB-EGF is involved in the PAF-induced transactivation
of EGFR.
Discussion
In the present study, we demonstrated that PAFR is
capable of stimulating the activation of EGFR and ERK1/2
in ovarian cancer cells endogenously expressing PAFR.
PAFR-mediated ERK1/2 activation appeared to be second-
ary to EGFR stimulation, as the EGFR tyrosine kinase
inhibitor AG1478 blocked PAF-induced ERK1/2 activa-
tion. However, the ERK1/2 activation induced through
PAF is not entirely dependent on EGFR stimulation. As
illustrated in the proposed model (Figure 7), the trans-
activation of the EGFR through PAF involves the PAFR,
the activation of PLCβ with downstream signaling through
Ca2+ mobilization, the tyrosine-protein kinase Src, matrix
metalloproteinase- dependent cleavage and the secretion
Figure 4 (See legend on next page.)
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Figure 4 Role of Ca2+ and PKC in responses to PAF in SKOV-3 cells. (A) SKOV-3 cells were pretreated for 1 h with the PLCβ inhibitor U73122
(20 μM) before stimulation with PAF (100 nM) or EGF (5 ng/ml) for 5 min. (B) SKOV-3 cells were pretreated for 1 h with the Ca2+ chelator BAPTA-
AM (20 μM) before stimulation with PAF (100 nM) or thapsigargin (1 μM) for 5 min. (C) SKOV-3 cells were loaded with the calcium probe Fura-2/
AM followed by stimulation with 100 nM PAF. (D) SKOV-3 cells were loaded with the calcium probe Fura-2/AM followed by stimulation with 100 nM
PAF in the presence or absence of WEB2086, calcium mobilization was assayed by monitoring the change in Fura-2/AM fluorescence. (E and F)
SKOV-3 cells were pretreated for 1 h with the PKC inhibitor GF109203X (5 μM) before stimulation with PAF (100 nM) or PMA (1 μM) for 5 min. Cells
were then harvested and subjected to Western blot analysis. The data shown are representative of at least three independent experiments. Data were
analyzed by Student’s t-test. * p < 0.05.
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phosphorylates ERK1/2. The transactivation of EGFR
through other G-protein coupled receptors (GPCR) is an
important signaling pathway for the induction of both
mitogenic and motogenic effects, suggesting a mechanism
for the proliferative effects of PAF in ovarian cancer cells.Figure 5 Effect of Src and MMP inhibitors on EGFR phosphorylation.
or 25 min. Following PAF treatment, cells were lysed and lysates were eval
expression and are expressed as the fold change (average ± S.E.M.) in phos
phosphor/total-EGFR are shown. (B) SKOV-3 cells were treated with the Src
or EGF (5 ng/ml) for 5 min. Cells were harvested and subjected to Western bl
inhibitor GM6001 (20 μM). Cells were then stimulated with either PAF (10
immunoblotting. (D) SKOV-3 cells were pretreated for 1 h with increasing
they were harvested and subjected to Western blot. The data shown are
analyzed by Student’s t-test. * p < 0.05.As a member of G-protein coupled receptors, PAFR
is involved in many biological functions, including
inflammation, cell growth, chemotaxis and oncogenesis.
Several recent reports provide evidences linking inflam-
mation and cancer promotion [40,41]. Inflammatory
moleculars, such as PAF and LPA, in the tumor(A) SKOV-3 cells were treated with 100 nM PAF for 0, 5, 10, 15, 20,
uated by Western blotting. Data were normalized to total Src protein
pho-Src compared to vehicle-treated cells. Representative blots for
inhibitor PP2 (20 μM) for 1 hour before stimulation with PAF (100 nM)
ot. (C) SKOV-3 cells were pretreated for 1 h with the metalloproteinase
0 nM) or EGF (5 ng/ml) for 5 min before they were harvested and
concentrations of the metalloproteinase inhibitor GM6001 before
representative of at least three independent experiments. Data were
Figure 6 Release of HB-EGF contributes to PAF-mediated EGFR transactivation. (A) SKOV-3 cells were treated with the HB-EGF neutralizing
antibody (50 μg/ml) for 1 hour before stimulation with PAF (100 nM) or EGF (5 ng/ml) for 5 min, cells were lysed and lysates were evaluated by
Western blotting. Data were normalized to total EGFR protein expression and are expressed as the fold change (average ± S.E.M.) in phospho-EGFR
compared to vehicle-treated cells. Representative blots for phosphor/total-EGFR are shown. (B) SKOV-3 cells were treated with PAF (100 nM) for the
indicated time (30 min to 12 h) while measuring HB-EGF production. (C) SKOV-3 cells were serum starved and then pretreated with 20 μM GM6001 or
HB-EGF neutralizing antibody (50 μg/ml) for 1 h. cells were then stimulated with 100 nM PAF for 2 h. The medium was harvested, and the amount of
HB-EGF was measured. Bars represent the average of triplicates ± S.D.; * p < 0.05 indicate a statistically significant difference compared to the
untreated control.
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and invasion in several cancers, including ovarian can-
cer [42,43]. The GPCR-mediated transactivation of
EGFR leads to the downstream activation of ERK1/2.
Depending on the cell type and the GPCR ligand,
ERK1/2 might be activated via EGFR-dependent and/or
EGFR-independent mechanisms [44,45]. In the present
study, we observed that PAF-induced ERK1/2 phos-
phorylation can be inhibited with the EGFR tyrosine
kinase inhibitor AG1478, but this inhibition was slightly.
In addition, increasing concentrations of AG1478, did not
lead to the obvious inhibition of ERK1/2 phosphorylation.
These results suggest that there might be other mecha-
nisms of PAF-induced ERK1/2 activation.Figure 7 Proposed model of the mechanisms involved in PAF-mediated
to PAF, activated PAFR triggers the EGFR/ERK transactivation pathway via PLC
HB-EGF. PAF also triggers the PKC pathway to couple to ERK phosphorylationWhen G-protein coupled receptors were activated,
downstream PLCβ could regulate cellular functions
through two distinct pathways involving the DAG-
mediated activation of PKC and the InsP3-induced
release and elevation of cytosolic Ca2+, respectively. Our
findings suggest that in the SKOV-3 cells, PAF-induced
EGFR transactivation was mediated through Ca2+, as
the PKC activator PMA did not mimic this effect and
the PKC blocker GF109203X did not inhibit this effect.
However, thapsigargin, which elevates intracellular Ca2+,
mimicked the PAF effect, and the Ca2+ chelator BAPTA-
AM blocked the transactivation of EGFR phosphoryl-
ation. However, the PKC activator PMA activated the
phosphorylation of ERK, and the phosphorylation of ERKEGFR transactivation in SKOV-3 ovarian cancer cells. In response
β, intracellular Ca2+, Src and the ADAM-mediated release of EGFR ligand
.
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that PAF activates ERK, the downstream target of EGFR,
via PLCβ-dependent PKC and MMP-mediated EGFR
pathways to promote ovarian cancer progression.
In different types of cells, both ligand-dependent and
ligand-independent mechanisms mediate EGFR transac-
tivation [46]. Ligand-dependent mechanisms involve the
release of EGFR agonists through the cleavage and shed-
ding of membrane-associated precursors by proteinases of
the ADAM family [47]. Ligand-independent mechanisms
have been reported to involve intracellular molecules,
including Src family kinases and Pyk2 [48,49]. In the
SKOV-3 cells, we observed that Src inhibitors abolished the
PAF-induced phosphorylation of the EGFR. In contrast,
these inhibitors only slightly affected the response to EGF,
suggesting a role for Src in the transactivation of EGFR
in SKOV-3 cells. We also observed the involvement of
HB-EGF shedding in the transactivation of EGFR after
PAF stimulation, as pretreatment with the metallopro-
teinase inhibitor GM6001 almost completely prevented
the PAF-induced, but not EGF-induced, phosphoryl-
ation of EGFR in these cells. HB-EGF is released after
PAF treatment, and increased HB-EGF concentrations
are blocked through the metalloproteinase inhibitor
GM6001. These results indicate that in the SKOV-3
cells, Src is involved in the activation of ADAMs, rather
than directly stimulating the EGFR, thus combining
these two mechanisms.
EGFR is expressed at high levels in ovarian cancer,
where signaling through EGFR contributes to cell sur-
vival, proliferation and invasion. The inhibition of EGFR
alone, has resulted in limited antitumor effects when
tested as a monotherapy in clinical trials. In addition to
receptor tyrosine kinase, PAFR regulates the responsive-
ness of cancer cells to the ligand PAF. It has become
increasingly evident that the crosstalk between PAFR
and EGFR confer an aggressive tumorigenic phenotype
in cancer cells. In the present study, we have shown that
the activation of both PAFR and EGFR induces the
phosphorylation of the MAPK pathway, and PAF mediates
the transactivation of EGFR. Indeed, combined treatment
with an EGFR tyrosine kinase inhibitor and the PAFR
antagonist resulted in additive antitumor effects. We have
shown that PAF stimulates ERK1/2 through different
mechanisms, acting by PAFR-mediated EGFR transacti-
vation in ovarian cancer cells. This evidence further
confirms the diversity of intracellular crosstalk and under-
scores the importance of investigating these mechanisms
to better understand signaling in cancer cells.
Conclusions
In the present study, we demonstrated that PAF transac-
tivates EGFR through PAFR in both time- and dose-
dependent manners in the SKOV-3 ovarian cancer cells.EGFR transactivation was dependent on the PAF-receptor,
PLCβ, Ca2+, Src and the ADAM-mediated release of
HB-EGF. These results support the development of
therapeutic strategies involving the combined EGFR
and PAFR targeting in ovarian cancer.
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